SCHEMBL2170681

SCHEMBL2170681

Cc1nc2c(ccc3ccccc32)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.53
NPC1 O15118 2/20 0.53
XIAP P98170 1/20 0.48
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HCRTR1 O43613 1/20 0.45
LMNA P02545 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 1/20 0.44
TLR8 Q9NR97 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
HSD17B10 Q99714 3/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
TSHR P16473 4/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29843187 1.00 RAB9A (0.53) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL4139521 0.98 RAB9A (0.51) RAB9ANPC1XIAPMAPTSMN1; SMN2
Iodomethane SCHEMBL9193628 0.96 RAB9A (0.50) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL9300730 0.91 RAB9A (0.57) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL26217317 0.87 RAB9A (0.46) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL8408656 0.82 RAB9A (0.45) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL17281460 0.81 NPC1 (0.72) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL9301190 0.80 XIAP (0.48) RAB9ANPC1XIAPMAPTSMN1; SMN2
SCHEMBL20669005 0.79 NPC1 (0.70) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL12930243 0.79 NPC1 (0.57) RAB9ANPC1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106701063-B A kind of controllable organic solid-state luminescent material, preparation method and applications 三峡大学 2019-05-14 CN claimed
CN-106701063-A Controllable organic solid-state luminescent material as well as preparation method and application of controllable organic solid-state luminescent material 三峡大学 2017-05-24 CN claimed
US-20170056376-A1 SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE UNIV CALIFORNIA (US) 2017-03-02 US claimed
WO-2015164816-A2 SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL KCA3.1 AND THEIR METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-10-29 WO claimed
EP-1087952-B1 BENZAZOLE COMPOUNDS AND THEIR USE NOVARTIS AG (CH) 2004-06-02 EP claimed
US-6410578-B1 INSECTICIDE, MITICIES, PESTICIDE NOVARTIS ANIMAL HEALTH US, INC. 2002-06-25 US claimed
CN-1302293-A Benzazole compounds and their use NOVARTIS AG (CH) 2001-07-04 CN claimed
EP-1087952-A1 BENZAZOLE COMPOUNDS AND THEIR USE Novartis AG (CH) 2001-04-04 EP claimed
WO-1999065886-A1 BENZAZOLE COMPOUNDS AND THEIR USE NOVARTIS AG (CH) 1999-12-23 WO claimed
US-4124386-A Color diffusion transfer receiving layer comprising polymeric quaternary n-heterocyclic mordant FUJI PHOTO FILM CO., LTD. (JP) 1978-11-07 US claimed
US-3943142-A Dye intermediates and their preparation and use in the synthesis of methine dyes EASTMAN KODAK COMPANY (US) 1976-03-09 US claimed
JP-7118248-A None JP disclosed
JP-6220028-A None JP disclosed
US-12629356-B2 Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof IOVANCE BIOTHERAPEUTICS, INC. (US) 2026-05-19 US disclosed
EP-3565586-B1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF IOVANCE BIOTHERAPEUTICS INC (US) 2025-10-08 EP disclosed
US-4290870-A 5-ISOXOLONE, AROMATIC CARBONYL, DIALKYLAMINO AROMATIC CARBONYL OR FUJI PHOTO FILM CO., LTD. (JP) 1981-09-22 US disclosed
EP-0034279-A2 Sulfoalkylating agents, process for their preparation and their use in the manufacture of quanternary sulfoalkyl salts Agfa-Gevaert AG (DE) 1981-08-26 EP disclosed
US-4124386-A Color diffusion transfer receiving layer comprising polymeric quaternary n-heterocyclic mordant FUJI PHOTO FILM CO., LTD. (JP) 1978-11-07 US disclosed
US-3961952-A ELECTROPHOTOGRAPHY, SUPPORTS, COATINGS ITEK CORPORATION (US) 1976-06-08 US disclosed
US-3943142-A Dye intermediates and their preparation and use in the synthesis of methine dyes EASTMAN KODAK COMPANY (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629356-B2 Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof PBK, IL2, KCNN3 RAB9A 4594/4885NPC1 1565/4885XIAP 3730/4885
US-20170056376-A1 SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE KCNN3, KCNN1, KCNN2 RAB9A 3176/4885NPC1 2863/4885XIAP 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.